Terms: = Germ cell tumor AND NR4A3, MINOR, 8013, ENSG00000119508, Q92570, CHN, NOR1, CSMF AND Clinical Outcome
15 results:
1. Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients.
Zhang J; Kulkarni HR; Singh A; Niepsch K; Müller D; Baum RP
J Nucl Med; 2019 Mar; 60(3):377-385. PubMed ID: 30115686
[TBL] [Abstract] [Full Text] [Related]
2. Long-term Results after CT-Guided Percutaneous Ethanol Ablation for the Treatment of Hyperfunctioning Adrenal Disorders.
Frenk NE; Sebastianes F; Lerario AM; Fragoso MC; Mendonca BB; Menezes MR
Clinics (Sao Paulo); 2016 Oct; 71(10):600-605. PubMed ID: 27759849
[TBL] [Abstract] [Full Text] [Related]
3. Immune-escape markers in relation to clinical outcome of advanced melanoma patients following immunotherapy.
Tjin EP; Krebbers G; Meijlink KJ; van de Kasteele W; Rosenberg EH; Sanders J; Nederlof PM; van de Wiel BA; Haanen JB; Melief CJ; Vyth-Dreese FA; Luiten RM
Cancer Immunol Res; 2014 Jun; 2(6):538-46. PubMed ID: 24894091
[TBL] [Abstract] [Full Text] [Related]
4. Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstem and nonbrainstem gliomas.
Pollack IF; Jakacki RI; Butterfield LH; Hamilton RL; Panigrahy A; Potter DM; Connelly AK; Dibridge SA; Whiteside TL; Okada H
J Clin Oncol; 2014 Jul; 32(19):2050-8. PubMed ID: 24888813
[TBL] [Abstract] [Full Text] [Related]
5. "Combined" desmoplastic melanoma of the vulva with poor clinical outcome.
Collina G
Pathologica; 2011 Dec; 103(6):337-9. PubMed ID: 22558891
[TBL] [Abstract] [Full Text] [Related]
6. Isolated limb infusion with melphalan and actinomycin D in melanoma patients: factors predictive of acute regional toxicity.
Kam PC; Thompson JF
Expert Opin Drug Metab Toxicol; 2010 Sep; 6(9):1039-45. PubMed ID: 20604735
[TBL] [Abstract] [Full Text] [Related]
7. tumor necrosis factor-like weak inducer of apoptosis stimulation of glioma cell survival is dependent on Akt2 function.
Fortin SP; Ennis MJ; Savitch BA; Carpentieri D; McDonough WS; Winkles JA; Loftus JC; Kingsley C; Hostetter G; Tran NL
Mol Cancer Res; 2009 Nov; 7(11):1871-81. PubMed ID: 19861406
[TBL] [Abstract] [Full Text] [Related]
8. MYCN promotes the expansion of Phox2B-positive neuronal progenitors to drive neuroblastoma development.
Alam G; Cui H; Shi H; Yang L; Ding J; Mao L; Maltese WA; Ding HF
Am J Pathol; 2009 Aug; 175(2):856-66. PubMed ID: 19608868
[TBL] [Abstract] [Full Text] [Related]
9. [Selective embolization and surgical resection for head and neck glomus tumours--clinical outcome analysis].
Girolami G; Heuser L; Hildmann H; Sudhoff H
Laryngorhinootologie; 2008 Mar; 87(3):181-5. PubMed ID: 18098102
[TBL] [Abstract] [Full Text] [Related]
10. clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial.
Yamanaka R; Homma J; Yajima N; Tsuchiya N; Sano M; Kobayashi T; Yoshida S; Abe T; Narita M; Takahashi M; Tanaka R
Clin Cancer Res; 2005 Jun; 11(11):4160-7. PubMed ID: 15930352
[TBL] [Abstract] [Full Text] [Related]
11. Evaluation of 11C-methionine PET as a surrogate endpoint after treatment of grade 2 gliomas.
Ribom D; Schoenmaekers M; Engler H; Smits A
J Neurooncol; 2005 Feb; 71(3):325-32. PubMed ID: 15735925
[TBL] [Abstract] [Full Text] [Related]
12. Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma.
Peterson AC; Harlin H; Gajewski TF
J Clin Oncol; 2003 Jun; 21(12):2342-8. PubMed ID: 12805336
[TBL] [Abstract] [Full Text] [Related]
13. outcomes analysis in patients undergoing laparoscopic adrenalectomy for hormonally active adrenal tumors.
Brunt LM; Moley JF; Doherty GM; Lairmore TC; DeBenedetti MK; Quasebarth MA
Surgery; 2001 Oct; 130(4):629-34; discussion 634-5. PubMed ID: 11602893
[TBL] [Abstract] [Full Text] [Related]
14. Comparison of one-, two-, and three-dimensional measurements of childhood brain tumors.
Warren KE; Patronas N; Aikin AA; Albert PS; Balis FM
J Natl Cancer Inst; 2001 Sep; 93(18):1401-5. PubMed ID: 11562391
[TBL] [Abstract] [Full Text] [Related]
15. Active-specific immunotherapy for melanoma.
Mitchell MS; Harel W; Kempf RA; Hu E; Kan-Mitchell J; Boswell WD; Dean G; Stevenson L
J Clin Oncol; 1990 May; 8(5):856-69. PubMed ID: 2139701
[TBL] [Abstract] [Full Text] [Related]
